BBIO241220C35000
- 0.10
- -0.02-16.67%
BridgeBio Pharma Newsroom
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Receives Buy Rating Following Attruby's FDA Approval and Strategic Milestones
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $55
Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $48
B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $45
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $58
BridgeBio Pharma Analyst Ratings
BridgeBio Pharma's Hold Rating: Balancing Optimism From Acoramidis Approval With Market and Competitive Concerns
BridgeBio Pharma (BBIO) Receives a Buy From Piper Sandler
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $40
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
BridgeBio Pharma (BBIO) Gets a Buy From Scotiabank
Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
Promising Phase 3 Results for Acoramidis Support Buy Rating for BridgeBio Pharma Despite Study Limitations
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $45
BridgeBio Pharma Analyst Ratings
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $45
Analysts Are Neutral on These Healthcare Stocks: Fate Therapeutics (FATE), BridgeBio Pharma (BBIO)